Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 8/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5863996 | 0.91 | ALDH1A1 (0.39) | ALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL5863779 | 0.89 | TDP1 (0.36) | MAPTTDP1PTGS1PTGS2 | |
| SCHEMBL5754107 | 0.88 | ALDH1A1 (0.41) | ALDH1A1KDM4EHPGDTDP1PTGS1 | |
| SCHEMBL4533965 | 0.88 | KIF11 (0.41) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL5864327 | 0.87 | CYP2C19 (0.40) | ALDH1A1TDP1PTGS1PTGS2 | |
| SCHEMBL5786959 | 0.87 | L3MBTL1 (0.37) | ALDH1A1MAPTKDM4EHPGDTDP1 | |
| SCHEMBL5752888 | 0.86 | KIF11 (0.41) | KDM4EHPGDTDP1PTGS1PTGS2 | |
| SCHEMBL5863739 | 0.86 | MAPK8 (0.38) | ALDH1A1KDM4ETDP1PTGS1PTGS2 | |
| SCHEMBL5754034 | 0.85 | GRIN1 (0.39) | KDM4ETDP1PTGS1PTGS2 | |
| SCHEMBL5864291 | 0.82 | TDP1 (0.42) | ALDH1A1MAPTKDM4EHPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041676-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-20060019988-A1 | Compounds for treating cell prolifieration disease with of kinesin activity , anticancer activity | CYTOKINETICS, INC. | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019988-A1 | Compounds for treating cell prolifieration disease with of kinesin activity , anticancer activity | KIF5B, KIF2C, KIF18A | PDE4A 1529/4885PDE4B 1678/4885PDE4C 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.